Benign Prostatic Hyperplasia (BPH)

Reimbursement Support

Reimbursement Codes and Allowables

Reimbursement Guide

Patient Education

Prostate Diseases

Prostate Cancer

Benign Prostatic Hyperplasia (BPH)

Prostatitis

Helpful Links

Patient FAQs

Patient Information from Package Insert

Androgen Reduction Graph

Physician Information


	Bayer Global
	Bayer Corporate - USA

	general conditions of use privacy statement imprint © 2007 Bayer HealthCare Pharmaceuticals

Physician Support
Benign Prostatic Hyperplasia (BPH)

Viadur is indicated in the palliative treatment of advanced prostate cancer and not for benign prostatic hyperplasia. Bayer is not responsible for, and does not endorse, any of the information found on this page.

Benign Prostatic Hyperplasia (BPH)

Benign prostatic hyperplasia (BPH) is the abnormal growth of benign (not cancerous) prostate cells.¹ In BPH, the prostate grows larger and pushes against the urethra and bladder, blocking the normal flow of urine.² More than half of the men in the U.S. between the ages of 60 and 70 have symptoms of BPH.³ Although this condition is seldom a threat to life, it may require treatment to relieve symptoms.

What are some problems BPH can lead to?

BPH can sometimes lead to bothersome problems with urination, such as frequent daytime and nighttime urination, dribbling, and difficulty starting and stopping urine flows.⁴

How do I choose a treatment?

Typically, the options to treat BPH depend on what the man prefers.⁵ As with other diseases of the prostate, the most important part of treatment is regularly meeting with your doctor and discussing your current symptoms. For instance, some men want immediate relief and are willing to undergo surgery or try a drug regimen to get relief.⁶ Some men also want to start taking drugs, even if their only symptom is an elevated prostate specific antigen (PSA) level.⁷ PSA, a protein produced in prostate cells, is frequently present in elevated levels in men who have a prostate disease.⁸ Others are reluctant, often unwilling, to undergo surgery or to take pills daily for an extended period.

Call the doctor if:

PHYSICIANS- Feel free to add your personal comments here.

Doctor’s instructions:

PHYSICIANS- Feel free to add your personal comments here.

Viadur is indicated in the palliative treatment of advanced prostate cancer and not for benign prostatic hyperplasia.

Printer-Friendly Version

References


	Important Safety Considerations Viadur is contraindicated in patients with hypersensitivity to Gn-RH, Gn-RH agonist analogs, or any of the components in Viadur. Viadur is contraindicated in women and pediatric patients and was not studied in women or children. Viadur, like other LH-RH agonists, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience a worsening of symptoms or onset of new symptoms including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction, and spinal cord compression. The most comment systemic side effects were hot flashes (67.9%), asthenia (7.6%), gynecomastia (6.9%), depression (5.3%), and sweating (5.3%). The most common local side effects were bruising (34.6%) and burning (5.6%).
	Distributed and Marketed by:	Manufactured by:
	Bayer HealthCare Pharmaceuticals 6 West Belt, Wayne, NJ 07470 USA
	© Copyright 2007 Bayer HealthCare Pharmaceuticals. Viadur is a trademark of ALZA Corporation under license to Bayer HealthCare Pharmaceuticals. DUROS® is a registered trademark of ALZA Corporation. The information provided on Bayer products is only intended for the United States audience. Regulatory requirements, regulations, laws, and distribution of information about drug products may vary from country to country. Product names and indications (product uses) also may be different in different countries. The prescribing information provided here is based on United States labeling and may not be appropriate outside of the United States.